Julie Hambleton
Director/Board Member bei IGM BIOSCIENCES, INC.
Vermögen: 260 435 $ am 31.03.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Daniel Lynch | M | 65 | 8 Jahre | |
| Fred Schwarzer | M | 72 | 21 Jahre | |
| Michael Varney | M | 65 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 19 Jahre |
| Akshay Nanduri | M | - |
Onc.ai, Inc.
 Onc.ai, Inc. Packaged SoftwareTechnology Services Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation. | - |
| Jonathan Lim | M | 52 | 6 Jahre | |
| Saqib Islam | M | 54 | 7 Jahre | |
| Felix Baker | M | 55 | 3 Jahre | |
| Michael Lee | M | 45 | 5 Jahre | |
| Thomas Hawes | M | 48 |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation. | - |
| T. S. Harigopal | M | - | 3 Jahre | |
| Jean Liu | F | 55 | 2 Jahre | |
| Jakob Haldor Topsøe | M | 55 | 6 Jahre | |
| Robert Shoemaker | M | 43 | 6 Jahre | |
| Kim Diamond | F | - | 6 Jahre | |
| Christina Teng Topsøe | F | 43 | 6 Jahre | |
| William Strohl | M | 71 | 6 Jahre | |
| Badreddin Edris | M | 37 | 6 Jahre | |
| Valerie Start | M | 64 | 5 Jahre | |
| Scott Morrison | M | 66 | 6 Jahre | |
| Christopher M. Duke | M | 52 |
Gennao Bio, Inc.
 Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | 3 Jahre |
| Paul A. Barsanti | M | - | 5 Jahre | |
| Chandra D. Lovejoy | F | 52 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 3 Jahre |
| Pratik Multani | M | 57 | 6 Jahre | |
| Jason Throne | M | 53 | 5 Jahre | |
| Alexander Casdin | M | 56 | 6 Jahre | |
| Alan Fuhrman | M | 67 | 5 Jahre | |
| Herschel Weinstein | M | 68 | 4 Jahre | |
| Freda Lewis-Hall | M | 69 | 7 Jahre | |
| Carlos Alban | M | 61 | 2 Jahre | |
| M. Wilsey | M | 71 | 5 Jahre | |
| James Bristol | M | 77 | 6 Jahre | |
| Theodore Samuels | M | 69 | 7 Jahre | |
| Wendy Yarno | F | 69 | 5 Jahre | |
| James Cassidy | M | 65 | 7 Jahre | |
| Ebun Garner | M | 52 | 3 Jahre | |
| Bruce Turner | M | 60 |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | 4 Jahre |
| David Chacko | M | 41 | 5 Jahre | |
| Steven Weber | M | 48 | 2 Jahre | |
| Bhavesh Ashar | M | 58 | 3 Jahre | |
| Angus M. Sinclair | M | - | 6 Jahre | |
| Rachel Cervantes | F | - | - | |
| Mindy Goldman | F | - |
The University of California, San Francisco
| 31 Jahre |
| Nik Chetwyn | M | - | 3 Jahre | |
| Brain Baker | M | - | - | |
| Suraj Mudichintala | M | - |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation. | - |
| Alison Milhous | F | 45 | - | |
| Les Brail | M | - | - | |
| Emir Sandhu | M | - |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation. | 4 Jahre |
| Fady Malik | M | 59 |
The University of California, San Francisco
| 24 Jahre |
| Lisa Decker | M | 55 | 3 Jahre | |
| Chris Takimoto | M | 65 | 3 Jahre | |
| Michael Nofi | M | 53 | 5 Jahre | |
| John Shiver | M | 66 | 3 Jahre | |
| Matthew Jacobson | M | - |
The University of California, San Francisco
| 22 Jahre |
| Juan-Pablo Mas | M | - |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation. | 2 Jahre |
| Mark Smith | M | 72 |
The University of California, San Francisco
| 30 Jahre |
| David A. Kessler | M | 72 |
The University of California, San Francisco
| 21 Jahre |
| Bruce Keyt | M | 71 | 14 Jahre | |
| Pamela Palmer | M | 61 |
The University of California, San Francisco
| 28 Jahre |
| Craig David Gordon | M | - |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | - |
| Jonathan Fleming | M | 66 |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation. | - |
| Bradley Campbell | M | 48 |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | 2 Jahre |
| Frank Perier | M | 64 | 5 Jahre | |
| Kristen Hege | M | 60 |
The University of California, San Francisco
| 28 Jahre |
| David Diaz-Casariego | M | - |
Onc.ai, Inc.
Onc.ai, Inc. Packaged SoftwareTechnology Services Onc.ai, Inc. is a digital health company that is privately held and is developing a precision oncology care management platform. The company is based in San Carlos, CA. The company aims to transform clinical decision making and is backed by premier investment firms such as the Blue Venture Fund, MassMutual Alternative Investments, and Accomplice, among others. The company is building a pipeline of physician-centered products to fulfill the potential of precision oncology. The company was founded by Akshay Nanduri, who has been the CEO since incorporation. | 1 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Stephen P. Squinto | M | 67 |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | 6 Jahre |
| Lamberto Andreotti | M | 73 | 19 Jahre | |
| William Ringo | M | 78 | 7 Jahre | |
| Julie Cherrington | M | 66 |
Arch Oncology, Inc.
 Arch Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Arch Oncology, Inc. develops drugs for life-threatening disorders. Its products include anti-CD47 monoclonal antibody, CD47 antisense oligonucleotide, and a small molecule CD47 inhibitor. The company was founded by William A. Frazier and Jeffrey S. Isenberg in 2006 and is headquartered in Brisbane, CA. | 3 Jahre |
| Ian Clark | M | 62 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 13 Jahre |
| Louis Lavigne | M | 75 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 23 Jahre |
| Sheila Gujrathi | M | 53 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 11 Jahre |
| Michael Loberg | M | 76 | 8 Jahre | |
| Pascal Soriot | M | 64 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | - |
| Luis Borges | M | 62 | 5 Jahre | |
| Jeffrey Schwartz | M | 45 | 6 Jahre | |
| Ryan Watts | M | 48 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 11 Jahre |
| Asha Das | M | 59 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 7 Jahre |
| Robert Garnick | M | 74 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 24 Jahre |
| Lindsey Rolfe | M | 56 | 13 Jahre | |
| June Lee | M | 58 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 7 Jahre |
| Anna L. Barry | M | - |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 8 Jahre |
| Daniel S. Chen | M | 55 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 15 Jahre |
| L. Smith | M | 57 | 7 Jahre | |
| Robert Steven Sikorski | M | - | 3 Jahre | |
| Kevin P. Baker | M | 63 | 12 Jahre | |
| Alejandro Dorenbaum | M | 64 |
The University of California, San Francisco
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 8 Jahre |
| Alexander Hardy | M | 56 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | - |
| Ingrid Boyes | F | - |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 10 Jahre |
| Sandra Horning | M | 75 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | - |
| John M. Whiting | M | 69 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 20 Jahre |
| Kapil Dhingra | M | 64 | 6 Jahre | |
| Marc Tessier-Lavigne | M | 64 |
The University of California, San Francisco
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 19 Jahre |
| Markus Gemuend | M | - |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | - |
| Brian Daniels | M | 65 | - | |
| Myrtle Potter | F | 65 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 5 Jahre |
| Stephen G. Juelsgaard | M | 75 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | 24 Jahre |
| S. Connelly | M | - |
The University of California, San Francisco
| 8 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 98 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Julie Hambleton
- Persönliches Netzwerk
